Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2

Highlights

- BA.1.1, BA.1, and BA.2 escape neutralization by two-dose mRNA vaccinee sera
- Booster vaccination recovers Omicron immunity to levels comparable to Delta
- Sera from Omicron, but not D614G or Delta, COVID-19 patients neutralize Omicron
- The Omicron “EPE214” insertion does not dictate neutralization resistance

Authors
John P. Evans, Cong Zeng, Panke Qu, ..., Kai Xu, Richard J. Gumina, Shan-Lu Liu

Correspondence
liu.6244@osu.edu

In brief
The emerging SARS-CoV-2 Omicron variants may threaten existing COVID-19 immunity. Evans and colleagues examine immunity against the BA.1.1 and BA.2 variants, as well as prior SARS-CoV-2 variants, in two- and three-dose vaccinated individuals and recovered COVID-19 patients. Booster vaccination, but not two-dose vaccinee or non-Omicron-infected patient sera, neutralizes Omicron.
Short Article

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2

John P. Evans,1,2,3,15 Cong Zeng,1,2,15 Panke Qu,1,2,15 Julia Faraone,1,2,3 Yi-Min Zheng,1,2 Claire Carlin,4 Joseph S. Bednash,5 Tongqing Zhou,6 Gerard Lozanski,7 Rama Mallampalli,8 Linda J. Saif,8,9,10 Eugene M. Oltz,11 Peter J. Mohler,4,12,13,14 Kai Xu,1,2 Richard J. Gumina,4,13,14 and Shan-Lu Liu1,2,10,11,16,*

1Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA
2Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
3Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA
4Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA
5Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA
6Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
7Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
8Center for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH 44691, USA
9Department of Veterinary Medicine, College of Veterinary Medicine, The Ohio State University, Wooster, OH 44691, USA
10Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210, USA
11Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA
12Frick Center for Heart Failure and Arrhythmia Research, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
13Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
14Department of Physiology and Cell Biology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
15These authors contributed equally
16Lead contact
*Correspondence: liu.6244@osu.edu
https://doi.org/10.1016/j.chom.2022.04.014

SUMMARY

Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reinvigorated concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicron sub-lineages, including BA.2, are comparably neutralized by Omicron patient sera. These results highlight the importance of booster vaccine doses for protection against all Omicron variants and provide insight into the immunity from natural infection against Omicron sub-lineages.

INTRODUCTION

Since the introduction of SARS-CoV-2 into the human population in late 2019, adaptive evolution of the virus has resulted in increased transmissibility and resistance to vaccine- or infection-induced neutralizing antibodies (Abdool Karim and de Oliveira, 2021; Singh et al., 2021). Indeed, the initial D614G mutation in the virus spike (S) protein enhanced virus stability, infectivity, and transmission (Plante et al., 2021; Yurkovetskiy et al., 2020). This initial adaptation was followed by the emergence of several SARS-CoV-2 variants of concern, including Alpha (B.1.1.7), which spread rapidly from Europe to become the dominant variant globally (Washington et al., 2021). Subsequently, the Beta (B.1.351) variant exhibited substantial resistance to neutralization (Zhou et al., 2021), although it failed to disseminate as widely. Later, the Delta (B.1.617.2) variant exhibited moderate neutralization resistance combined with enhanced transmissibility, driving its dominance worldwide (Mlcochova et al., 2021). Despite these evolutionary leaps, vaccine-mediated protection from severe disease and hospitalization remained high, potentially due to broader cell-based immunity (Liu et al., 2022a; Scobie et al., 2021).
Figure 1. The Omicron SARS-CoV-2 variant BA.1.1 exhibits strong vaccine-induced immune escape that is overcome by booster vaccination
(A) Diagrams of SARS-CoV-2 S variants used for pseudotyping, which indicate the location of specific mutations as well as the S1 and S2 subunits of S, the N-terminal domain (NTD), receptor binding domain (RBD), fusion peptide (FP), and transmembrane domain (TM).
(B) Sera from 48 HCWs collected 3–4 weeks after second mRNA vaccine dose were used to neutralize pseudotyped variants, and the resulting 50% neutralization titers (NT 50) are displayed.
(C) Heatmaps showing patient/vaccinee NT 50 values against each variant with patient numbers identified as “M” for Moderna mRNA-1273-vaccinated/boosted HCW and “P” for Pfizer/BioNTech BNT162b2-vaccinated/boosted HCW.

(legend continued on next page)
Emergence of the Omicron (B.1.1.529) variant has generated serious concern about the continued efficacy of vaccines, the future course of the pandemic, and a potential need for alternative vaccination strategies (Hoffmann et al., 2022; Karim and Karim, 2021; Liu et al., 2022b; Pulliam et al., 2022; Su et al., 2022). In addition to its sheer number of mutations (Sarkar et al., 2021), Omicron contains specific alterations that have been previously shown to impact vaccine resistance, namely in the receptor-binding domain (RBD), a primary target of host neutralizing antibodies to the S protein (Yu et al., 2020), as well as a number of other non-RBD mutations, including key mutations in the S2 subunit (Figure 1A) (Escalera et al., 2022). Moreover, emergence of the Omicron variant resulted in an unprecedented spike in COVID-19 cases, including a dramatic increase in vaccine-breakthrough infections (Karim and Karim, 2021; Kuhlmann et al., 2022), although the Omicron variant exhibited reduced virulence (Halfmann et al., 2022).

Concern over the Omicron variant was renewed following the identification of several Omicron sub-lineages with significant variations in their S proteins, including BA.1, BA.1.1, and BA.2 (Majumdar and Sarkar, 2022). While the constellation of mutations varies between isolates, the BA.1.1 lineage is defined by the presence of a single R346K mutation that is absent from the BA.1 lineage, whereas the BA.2 lineage is defined by key S mutations T19I, L24S, V213G, T376A, and R408S (Figure 1A) (Abbas et al., 2022). Although BA.1 was the major variant during the Omicron wave of the pandemic, the BA.2 variant, and to a lesser extent BA.1.1, has begun to account for an increasing proportion of cases (Latif et al., 2022). In particular, the BA.2 variant exhibits enhanced transmissibility relative to BA.1 and can reinfect previously BA.1-infected individuals (Lyngse et al., 2022; Stegger et al., 2022). To better characterize the immune escape of Omicron sub-lineages compared with other major SARS-CoV-2 variants, we examined neutralizing antibody responses in mRNA-vaccinated health care workers (HCWs), as well as hospitalized and ICU COVID-19 patients, against pseudotyped lentiviruses bearing the S of the D614G, Alpha, Beta, Delta, or Omicron variants.

RESULTS

Omicron BA.1.1 exhibits profound resistance to two-dose mRNA vaccination but is sensitive to neutralization after a booster dose

We initially examined the ability of Omicron BA.1.1 to escape vaccine-induced neutralizing antibodies, a critical measure of protection from SARS-CoV-2 infection (Khoury et al., 2021). To address this, we collected sera from 48 HCWs 3–4 weeks post-second dose of either Moderna mRNA-1273 (n = 20) or Pfizer/BioNTech BNT162b2 (n = 28) (Table 1). Having previously examined a similar cohort for the ability of the D614G, Alpha, Beta, and Delta variants to escape serum-neutralizing antibodies (nAbs) (Evans et al., 2022), we now performed a comparison with the Omicron BA.1.1 variant (see STAR Methods). We found that BA.1.1 exhibited significantly more neutralization resistance, i.e., 80.4-fold (p < 0.0001), compared to the ancestral D614G variant, with the Alpha, Beta, and Delta variants exhibiting a 1.3-fold, 5.1-fold (p < 0.0001), and 2.2-fold (p < 0.05) decrease in nAb titers, respectively (Figure 1B). In total, only 27.1% (13/48) of HCWs exhibited nAb titers against Omicron BA.1.1 above the detection limit (NT50 > 80) compared to that of other variants ranged between 91.7% and 100%; however, several individuals (1–3) exhibited strong nAb titers that were maintained against Omicron BA.1.1 (Figures 1B and 1C). Moderna mRNA-1273 in HCWs slightly outperformed Pfizer/BioNTech BNT162b2 (Figure S1A), as we have reported previously (Evans et al., 2022; Zeng et al., 2021a).

We further sought to examine booster-vaccination-induced immunity against Omicron BA.1.1 along with D614G, Alpha, Beta, and Delta for 19 HCWs with samples collected 9 months post-second dose and 1–11 weeks post-booster vaccination with homologous boosters of Moderna mRNA-1273 (n = 4) or Pfizer/BioNTech BNT162b2 (n = 15) (Table 1). We found that booster vaccination not only increased the nAb NT50 titer against all variants, including D614G, but also significantly restored neutralization of Omicron BA.1.1, with only 3.7-fold reduced NT50 relative to D614G (p < 0.0001), compared to a 4.2-fold reduction (p < 0.0001) for the Delta variant (Figures 1C and 1D). These data indicate that booster dose administration not only enhances nAb titers but also increases the breadth of the nAb response, especially against Omicron BA.1.1. Both post-second dose and post-booster dose samples were analyzed for 14 HCWS and showed significantly higher nAb titers following booster vaccination (Figures S1B–S1F). Pfizer/BioNTech BNT162b2-vaccinated HCWs exhibited no significant difference in NT50 titer compared to Moderna mRNA-1273-vaccinated HCWs post-booster (Figure S1G).

Omicron BA.1.1 is resistant to neutralization by D614G and Delta patient sera

We next examined nAb resistance of Omicron BA.1.1 and other major variants against COVID-19 patient sera collected during the 2020/D614G wave of the pandemic, prior to vaccination, as well as the 2021/Delta wave. For the ICU (n = 9) and hospitalized non-ICU (n = 9) patient serum samples collected during the 2020/D614G wave, we found that Omicron BA.1.1 was completely resistant to neutralization by patient serum samples, with only 22.2% (2/9) of ICU and 11.1% (1/9) of hospitalized non-ICU patients exhibiting a nAb titers above the limit of detection (Figures 2A and 2B). We further examined ICU patient samples (n = 18) collected during the Delta wave of the pandemic, including five infections confirmed as Delta by sequencing of virus from nasal swabs (Table 1). Serum from these infected patients exhibited potent neutralization of Delta, as would be expected, while Omicron BA.1.1 still exhibited strong resistance (Figures 2B and 2C). Although mean titers from these individuals were comparable to boosted HCWs, a more significant
proportion, i.e., 50.0% (9/18), exhibited no detectable nAb titers against Omicron BA.1.1 (Figures 2B and 2C). Further, this population contained one patient vaccinated and boosted with Moderna, four patients fully vaccinated with two doses of Pfizer, and four patients partially vaccinated with one dose of Pfizer, which dramatically out-performed unvaccinated patients against Omicron BA.1.1 and other variants, except Delta (Figures 2B and 2D).

Omicron BA.1.1 is effectively neutralized by Omicron patient sera

We next examined sera collected from 31 hospitalized patient samples collected during the Omicron wave of the pandemic (Table 1). Sera from these patients efficiently neutralized Omicron BA.1.1 with a higher efficiency against D614G and Alpha (p > 0.05) but showed 2- to 3-fold reduced neutralization against Beta and Delta (p < 0.05) (Figures 2B and 2E). We found that some patients exhibit broad immunity against all variants, whereas others exhibit strong immunity against Omicron BA.1.1 with minimal neutralization potency against the other variants (Figures 2B, S2A, and S2B). Among these Omicron patients, 15 were unvaccinated, 8 were vaccinated with two doses of Pfizer/BioNTech BNT162b2 (n = 4) or Moderna mRNA-1273 (n = 4), and eight were vaccinated and boosted with Pfizer/BioNTech BNT162b2. Interestingly, several unvaccinated patients exhibited broad neutralizing activity that was effective against earlier variants (Figures 2B and 2F). Differences between groups based on vaccination status were not significant (p > 0.05), although boosted patients exhibited higher NT50 compared to the unvaccinated, albeit this was not statistically significant (p > 0.05) (Figure 2F). We noted that the two-dose samples were collected between 5 and 11 months after the second vaccination (median 9 months), and that boosted samples were collected between 2 and 6 months (median 5 months) following the booster shot (Table 1), which might explain in part the lower levels of nAb for the second-dose and booster vaccination samples, as two-dose immunity has been shown to wane substantially by 6 months after vaccination (Evans et al., 2022).

Omicron BA.1 and BA.2 are resistant to neutralization by two-dose mRNA vaccination but sensitive to neutralization after a booster dose

With the identification of various Omicron sub-lineages, we tested their sensitivity to nAbs elicited by either mRNA vaccine, including booster, and Omicron infection. Specifically, we compared the BA.1.1 sub-lineage to the BA.1 sub-lineage, the most prominent lineage, and the BA.2 sub-lineage, which has

Table 1. Health care worker and Delta/Omicron COVID-19 patient summary information

|                         | HCWs with two doses (n = 48) | HCWs with three doses (n = 19) | HCWs for Omicron sub-lineage analysis (n = 10) | Delta wave ICU patients (n = 18) | Omicron wave hospitalized patients (n = 31) |
|-------------------------|-------------------------------|-------------------------------|-----------------------------------------------|---------------------------------|-------------------------------------------|
| **Sex** (n (% of total))|                               |                               |                                               |                                 |                                           |
| Female                  | 24 (50.0%)                    | 11 (57.9%)                    | 4 (40.0%)                                     | 6 (33.3%)                       | 11 (35.5%)                                |
| Male                    | 24 (50.0%)                    | 8 (42.1%)                     | 6 (60.0%)                                     | 12 (66.6%)                      | 20 (64.5%)                                |
| **Age in years (median, (range))** |                       |                               |                                               |                                 |                                           |
|                         | 36 (25–61)                    | 35 (22–48)                    | 37.5 (29–48)                                  | 60 (22–87)                      | 62 (28–78)                                |
| **Sample collection window** | December 2020–February 2021 | October 2021–November 2021   | January 2021–March 2021; October 2021–November 2021 | August 2021–December 2021      | February 2022–March 2022                  |
| **Vaccine type** (n (% of total)) |                           |                               |                                               |                                 |                                           |
| Moderna two doses        | 20 (41.7%)                    | N/A                           | 3 (30.0%)                                     | N/A                             | 4 (12.9%)                                 |
| Moderna three doses      | N/A                           | 4 (21.1%)                     | 3 (30.0%)                                     | 1 (5.6%)                        | N/A                                       |
| Pfizer two doses         | 28 (58.3%)                    | N/A                           | 7 (70.0%)                                     | N/A                             | 4 (12.9%)                                 |
| Pfizer three doses       | N/A                           | 15 (78.9%)                    | 7 (70.0%)                                     | 4 (22.2%)                       | 8 (25.8%)                                 |
| Johnson & Johnson one dose | N/A                         | N/A                           | N/A                                           | 1 (5.6%)                        | N/A                                       |
| **Sample collection timing** (median (range)) | |                               |                                               |                                 |                                           |
| Days after last dose for recipients of one dose | N/A                           | N/A                           | N/A                                           | 141                             | N/A                                       |
| Days after last dose for recipients of two doses | 26 (20–31)                   | N/A                           | 26.5 (22–28)                                  | 255 (204–254)                   | 274.5 (149–328)                           |
| Days after last dose for recipients of three doses | N/A                           | 21 (5–80)                     | 15 (7–80)                                     | 12                              | 158 (64–183)                              |
| Prior COVID-19 confirmed by PCR (n (% of total)) | 4 (8.3%)                      | 2 (10.5%)                     | 1 (10.0%)                                     | DNC                             | DNC                                       |

Displayed are summary data for the HCW samples collected post-second mRNA vaccine dose and post-booster mRNA vaccine dose. Additionally, summary data are displayed for the 10 HCW samples with both post-second and post-third dose samples collected and used in the analysis of Omicron variant sub-lineages. Finally, summary information is provided for the Delta wave and Omicron wave COVID-19 patients. Where it appears, N/A indicates “not applicable,” and DNC indicates “data not collected.”
Figure 2. The Omicron variant BA.1.1 exhibits strong immune escape from D614G- and Delta-infected, but not Omicron-infected, patients

(A) Sera from nine ICU COVID-19 patient samples and nine hospitalized non-ICU COVID-19 patient samples collected in 2020 prior to the approval of any SARS-CoV-2 vaccines were assessed for nAb titers.

(B) Heatmaps showing patient NT50 values against each variant. Patients are identified as “I” for ICU patient samples collected during the 2020 D614G wave and “H” for hospitalized non-ICU patient samples collected during the 2020 D614G wave; Delta wave ICU patients are identified as “U” for unvaccinated or “V” for vaccinated; and Omicron wave hospitalized non-ICU patients are identified as “U” for unvaccinated, “V” for two-dose vaccinated, and “B” for booster dose vaccinated.

(C) Sera from 18 ICU COVID-19 patient samples collected during the Delta wave of the pandemic were assessed for nAb titers.

(D) NT50 values for unvaccinated (n = 12) and vaccinated (n = 6) Delta wave COVID-19 ICU patients are plotted according to vaccination status.

(E) Sera from 31 hospitalized COVID-19 patient samples collected during the Omicron wave of the pandemic were assessed for nAb titers.

(F) NT50 values for unvaccinated (n = 15), two-dose-vaccinated (n = 8), and booster-vaccinated (n = 8) Omicron wave COVID-19-hospitalized patients are plotted according to vaccination status. Geometric mean NT50 values in (A) and (C)–(E) are displayed at the top of plots along with the percentage of patients with NT50 values above the limit of detection; bars represent geometric mean ±95% confidence interval, and significance relative to D614G is determined by one-way ANOVA followed by Tukey’s multiple comparisons. **P < 0.01, ***P < 0.001. (legend continued on next page)
been reported to exhibit further enhanced transmissibility and to induce breakthrough infections in patients previously infected with other Omicron lineages (Lyngse et al., 2022; Stegger et al., 2022). Additionally, we included a BA.1.1 mutant lacking the unusual EPE insertion at the position 214 of the Omicron spike (BA.1.1-ΔEPE) for comparison (see Figure 1A). For vaccine sera, we examined ten randomly selected HCW samples with both post-two-dose and post-booster-dose samples (Table 1). We observed comparable resistance of these sub-lineages and the BA.1.1-ΔEPE mutant to neutralization from both the two-dose-vaccinated and boosted HCWs (Figures 3A, 3B, and S3). Critically, and consistent with the pattern of BA.1.1 shown in Figure 1, BA.1. BA.1.1-ΔEPE, and BA.2 all exhibited reduced neutralization by the two-dose mRNA vaccination sera but showed an obviously increased sensitivity to neutralization by the booster dose sera (p < 0.05) (Figures 3A, 3B, and S3).

Omicron sub-lineages are comparably neutralized by Omicron patient sera

We next examined neutralization potency Omicron wave COVID-19 patient sera against the Omicron sub-lineages and observed comparable levels of neutralization for all Omicron sub-lineages (Figures 3C and S3). Again, the breadth of neutralization was heterogeneous across the patients examined, with some exhibiting strong neutralization of all variants (Figures 3D and S3) (n = 7), strong neutralization of only Omicron sub-lineages (Figures 3E and S3) (n = 2), or potent neutralization of ancestral D614G with weaker neutralization of Omicron sub-lineages (Figures 3F and S3) (n = 6). Additionally, a small subset of unvaccinated patients exhibited nAb repertoires that were most potent against BA.1- and BA.1.1-derived sub-lineages but were only weakly effective against the D614G and BA.2 lineages (Figures 3G and S3) (n = 4), and some patients exhibited no nAb response (Figure S3) (n = 12). Comparable levels of neutralization for all Omicron sub-lineages were also seen regardless of vaccination status (Figure S4).

DISCUSSION

In this work, we determined the efficacy of vaccine- and infection-induced immunity against Omicron sub-variants in parallel with other variants of concerns. We found that while recipients of two-doses of mRNA vaccines showed minimal neutralization of the Omicron BA.1.1 variant, recipients of a booster dose, either Moderna or Pfizer, exhibited much stronger neutralizing capacity against not only Omicron sub-lineages, but also against BA.1 and BA.2. This is consistent with prior reports for BA.1 (Jacobsen et al., 2021; Pérez-Then et al., 2022; Planas et al., 2022; Schmidt et al., 2022; Wang et al., 2022b; Xia et al., 2022) and a recent report on BA.2 (Yu et al., 2022). The fold difference between nAb titers against D614G and Omicron BA.1.1 in the boosted group (3.7-fold) versus the two-dose vaccine group (80.4-fold) revealed that a booster dose not only raises nAb levels but also increases the breadth of circulating nAbs. This conclusion is further supported by reports of an expanded B cell repertoire following booster vaccination or additional antigen exposures (Bednarski et al., 2022; Muecksch et al., 2022; Wang et al., 2022). While underlying mechanisms for this remain unclear, enhanced breadth of protection is likely due to additional affinity maturation following a third antigen exposure (Muecksch et al., 2021, 2022). Additionally, we were surprised to observe that the Delta variant exhibited slightly greater resistance to post-booster vaccination samples than the Omicron variant (p < 0.05). The reason underlying this difference is unclear but may reflect a broadened nAb repertoire following booster vaccination against all major variants of concern—however, the Omicron variant may exhibit a conformation that is relatively sensitive to antibody-mediated neutralization, due to a slightly more “open” and nAb-accessible conformation (Cerutti et al., 2022; Ye et al., 2022; Yin et al., 2022). As the Omicron variants may have evolved from a lineage distinct from Delta (Wang and Cheng, 2022), it is unsurprising that Omicron BA.1.1 exhibited strong resistance to nAb from unvaccinated Delta-infected ICU patients, with Omicron BA.1.1 exhibiting ~250-fold lower nAb sensitivity than Delta for this group. This is consistent with prior reports suggesting BA.1 exhibits strong escape from non-Omicron-infected patient sera (Seaman et al., 2022; Zhang et al., 2022; Zou et al., 2022).

Critically, we examined immunity following infection with the Omicron variant. These Omicron patients exhibit, unsurprisingly, strong potency of their nAbs against Omicron BA.1.1. However, these patient sera were largely effective against the D614G and Alpha variants, while Delta and Beta exhibited stronger resistance. Additionally, these hospitalized non-ICU Omicron wave patients exhibited lower nAb titers than the ICU Delta wave patients. The latter is unsurprising, as previous reports from our group and others (Chen et al., 2020; Legros et al., 2021; Zeng et al., 2020) have shown that the nAb response to SARS-CoV-2 infection is more robust with more severe disease. Furthermore, the Omicron variant is known to induce less severe COVID-19 compared to prior variants of concern (Halffmann et al., 2022; McMahan et al., 2022). We were surprised to find potent neutralization of early SARS-CoV-2 variants by some unvaccinated Omicron patients. Either a subset of unvaccinated Omicron patients develop a more broadly active nAb repertoire or these patients may have had prior SARS-CoV-2 infections with preceding variants. The latter possibility is likely, as Omicron has been shown to reinfect individuals with prior infections of previous SARS-CoV-2 variants (Pulliam et al., 2022; Zou et al., 2022). We also noted that two-dose and booster-vaccinated Omicron patients did not substantially outperform unvaccinated Omicron patients, and this was likely due to waning immunity during the extended time of sample collection after the vaccination—samples were collected 5–11 months (median 9 months) post-second dose and 2–6 months (median 5 months) post-booster dose, respectively. We have previously demonstrated substantial waning of immunity by 6 months post-second vaccine dose (Evans et al., 2022). The durability of booster-induced neutralizing antibodies remains to be investigated.
Figure 3. Omicron sub-lineages exhibit comparable relative immune escape from two-dose-vaccinated and booster-vaccinated HCW sera and show similar nAb titers in Omicron-infected patient sera

(A and B) Sera from 10 random HCWs collected post-two-dose vaccination (A) or post-booster vaccination (B) were assessed for nAb titers against D614G and the Omicron variant sub-lineages.

(C) Sera from 31 hospitalized COVID-19 patient samples collected during the Omicron wave of the pandemic were assessed for nAb titers against Omicron variant sub-lineages.

(D–G) Representative neutralization curves against D614G and the Omicron sub-lineages are shown for four representative patients hospitalized during the Omicron wave of the pandemic.

(H) NT50 values against each Omicron sub-lineage for unvaccinated (n = 15), two-dose vaccinated (n = 8), and boosted (n = 8) Omicron wave COVID-19 ICU-patients are plotted according to vaccination status. Geometric mean NT50 values in (A)–(C) and (H) are displayed at the top of plots along with the percentage of patients with NT50 values above the limit of detection; bars represent geometric mean ±95% confidence interval, and significance relative to D614G (A and B) or to BA.1.1 (C) is determined by one-way repeated measures ANOVA with Bonferroni’s multiple testing correction. Significance between vaccination statuses was determined by one-way ANOVA with Bonferroni’s multiple testing correction (H). P values are represented as *p < 0.05; ns, not significant.

See also Figure S3.
Additionally, we examined the major Omicron sub-lineages and observed largely comparable relative escape from two-dose-vaccinated and boosted COVID-19 sera and similar nAb titers in Omicron-infected patient sera. These findings indicate that the concerning BA.2 variant does not appear to exhibit enhanced immune escape compared to the more prevalent BA.1 or BA.1.1 variants; hence, the increasing frequency of BA.2 may be related to other mechanisms to enhance virus transmission. However, some Omicron patients exhibited narrow immunity that was only potent against the BA.1.1 and BA.1 variants. This is likely due to the substantial variation in RBD mutations between the BA.2 and BA.1.1/BA.1 sub-lineages. Further, the key R346K mutation that distinguishes BA.1.1 and BA.1, as well as the unusual EPE insertion mutation, which is present in all of these sub-lineages, does not seem to have a substantial impact on virus neutralization sensitivity. The largely similar neutralization of the Omicron sub-lineages was consistent across all vaccination groups including unvaccinated, two-dose recipients, and booster dose recipients.

Overall, our report highlights the need for booster dose administration to better combat the emerging Omicron variant and highlights that reformulation of existing mRNA vaccines to target Omicron BA.1.1, BA.2, or BA.2 may not be necessary with a three-dose vaccine regimen. However, the emergence of future divergent variants may further compromise even boosted immunity, or this immunity may wane over time. Indeed, continued monitoring of emerging SARS-CoV-2 variants is vital to allow for rapid investigation of their transmissibility, neutralization resistance, and pathogenicity.

Limitations of this study include the use of a pseudotyped virus system for determining nAb titers. While pseudotyped virus systems allow for easy comparison of several variant spike proteins and our neutralization assay has been demonstrated to correlate with infectious SARS-CoV-2 virus neutralization assays (Zeng et al., 2020), such a pseudotyped virus system may not fully recapitulate infectious SARS-CoV-2. In particular, the role of other SARS-CoV-2 proteins beyond spike in altering virus infectivity is not captured by the pseudotyped virus system. Further, the use of HEK293T-ACE2 cells as target cells, rather than primary cells, may not reflect the in vivo virus entry pathway, as SARS-CoV-2 entry in HEK293T-ACE2 cells is known to be biased toward the endosomal compartment rather than the plasma membrane. However, use of this cell line for neutralization is common and should not have artificial effects on calculating the nAb titers. During the course of study, five Delta wave patients provided nasal swab samples with detectable viral RNA for sequencing to confirm variants, and no nasal swab samples were collected for the Omicron wave patients. However, during the window of sample collection for the Delta wave patients and Omicron wave patients, each respective variant accounted for >99.9% of cases sequenced in Ohio during the same window. Overall, we demonstrate the necessity of a three-dose mRNA vaccine regimen for expanding nAb breadth and titer to a level protective against all major SARS-CoV-2 variants and superior to protection elicited by natural infection with the D614G, Delta, or Omicron variants.
REFERENCES

Abbas, Q., Kusakin, A., Sharrouf, K., Jyakhwo, S., and Komissarov, A.S. (2022). Follow-up investigation and detailed mutational characterization of the SARS-CoV-2 Omicron variant lineages (BA.1, BA.2, BA.3 and BA.1.1). Preprint at bioRxiv. https://doi.org/10.1101/2022.02.25.481941.

Abdol Karim, S.S., and de Oliveira, T. (2021). New SARS-CoV-2 variants - clinical, public health, and vaccine implications. New Engl. J. Med. 384, 1866–1868. https://doi.org/10.1056/nejmc2100362.

Bednarski, E., Del Rio Estrada, P.M., DaSilva, J., Boukadida, C., Zhang, F., Villalobos, Y.A.L., Range, X.R., Isidro, E.P., Garcia, E.L., Rivera, D.D., et al. (2022). Antibody and memory B-cell immunity in a heterogeneously infected and vaccinated population. Preprint at medRxiv. https://doi.org/10.1101/2022.02.07.2207062.

Cerutti, G., Guo, Y., Liu, L., Liu, L., Zhang, Z., Luo, Y., Huang, Y., Wang, H.H., Ho, D.D., Sheng, Z., and Shapiro, L. (2022). Cytomegalovirus mRNA vaccine booster dose. Lancet 396, 625–626. https://doi.org/10.1016/s0140-6736(22)00909-3.

Latif, A.A., Mullen, J.L., Akuzwenyi, T., Tseng, G., Cano, M., Haag, E., Zhou, J., Zeller, M., Hufbauer, E., Matteson, N., et al. (2022). Omicron variant report (outbreakinfo).

Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigail, J., Pillet, S., Grattard, F., Gonzalo, S., Verhoeven, P., et al. (2021). A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 18, 318–327. https://doi.org/10.1016/s1474-9322(21)00588-2.

Liu, J., Chandrashekar, A., Seliers, D., Barrett, J., Jacob-Dolan, C., Litton, M., McMahan, K., Sciaccia, M., VanWyk, H., Wu, C., et al. (2022a). Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493–496. https://doi.org/10.1038/s41586-022-04465-y.

Liu, Z., Chan, J.F.W., Zhou, J., Wang, M., Wang, Q., Zhang, G., Xu, W., Chik, K.K.H., Zhang, Y., Wang, Y., et al. (2022b). A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res. 1–3. https://doi.org/10.1016/j.cre.2022.02.006-031.

Lynge, F.P., Kirkeby, C.T., Denwood, M., Christiansen, L.E., Malbik, K., Malier, C.H., Skov, R.L., Krause, T.G., Rasmussen, M., Sieber, R.R., et al. (2022). Transmission of sars-cov-2 omicron voc subvariants BA.1 and BA.2: Evidence from danish households. Preprint at medRxiv. https://doi.org/10.1101/2022.01.28.22270044.

Majumdar, S., and Sarkar, R. (2022). Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J. Med. Virol. 94, 1777–1779. https://doi.org/10.1002/jmv.27558.

Mrazov, D., Illinskaya, A., Heidegger, G., Lloyd, P., and Derse, D. (2010). Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog. 6, e1000788. https://doi.org/10.1371/journal.ppat.1000788.

McMahan, K., Giffin, V., Tostanoski, L.H., Chung, B., Siamatou, M., Suthar, M.S., Halfmann, P., Kawaoka, Y., Piedra-Mora, C., Jain, N., et al. (2022). Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med (N Y) 3, 262–268.e4. https://doi.org/10.1016/j.med.2022.03.004.e264.

Micochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., Singh, S., et al. (2021). SARS-CoV-2 B1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119. https://doi.org/10.1038/s41586-021-410394-y.

Muecksf, F., Wang, Z., Cho, A., Gaebeler, C., Tanfous, T.B., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022). Increased potency and breadth of SARS-CoV-2 neutralizing antibodies after a third mRNA vaccine dose. Preprint at bioRxiv. https://doi.org/10.1101/2022.02.14.480394.

Muecksf, F., Weisblum, Y., Barnes, C.O., Schmidt, F., Schaefter-Babajew, D., Wang, Z., Lorenzi, J.C., Flyak, A.I., DeLaitsch, A.T., Huey-Tubman, K.E., et al. (2021). Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853–1868.e7. https://doi.org/10.1016/j.immuni.2021.07.008.e1857.

Pérez-Then, E., Lucas, C., Monteiro, V.S., Miric, M., Brache, V., Cocon, L., Vogels, C.B.F., Malik, A.A., De la Cruz, E., Jorge, A., et al. (2022). Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 28, 481–485. https://doi.org/10.1038/s41591-022-01705-6.

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchnieser, J., Bolland, W.H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022). Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675. https://doi.org/10.1038/s41586-021-04389-2.

Plante, J.A., Liu, Y., Liu, J., Xia, H., Johnson, B.A., Lokugamage, K.G., Zhang, X., Muruato, A.E., Zou, J., Fontes-Garillas, C.R., et al. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121. https://doi.org/10.1038/s41586-020-2895-3.

Pulliam, J.R.C., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, M.J., Dushoff, J., Milissa, K., and Moutrite, H. (2022). Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science, eaavn4947. https://doi.org/10.1126/science.abavn4947.
Jansen, K.U., Xie, X., et al. (2022). Neutralization and durability of 2 or 3 doses of SARS-CoV-2. Preprint at medRxiv. https://doi.org/10.1038/s41591-021-01397-4.

Preprint at medRxiv. https://doi.org/10.1101/2022.02.19.22271112.

Stegger, M., Edslev, S.M., Sieber, R.N., Ingham, A.C., Ng, K.L., Tang, M.-H.E., Barrett, K.M., Larsen, B.B., Anderson, C., White, S., Cassens, T., et al. (2021). Monitoring emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell Host & Microbe 184, 2348–2361.e6. https://doi.org/10.1016/j.chom.2021.02.037.e2354.

Zou, J., Xia, H., Xie, X., Kurhade, C., Machado, R.R.G., Weaver, S.C., Ren, P., and Shi, P.Y. (2022). Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun. 13, 852. https://doi.org/10.1038/s41467-022-28644-w.
**STAR METHODS**

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Chemicals, peptides, and recombinant proteins** | | |
| Coelenterazine | GoldBio | Cat#: CZ2.5, CAS: 55779-48-1 |
| Dulbecco’s Modified Eagles Medium (DMEM) | Gibco | Cat#: 11965-092 |
| Fetal Bovine Serum (FBS) | Sigma | Cat#: F1051 |
| Penicillin-streptomycin | HyClone | Cat#: SV30010 |
| Dulbecco’s Phosphate Buffer Saline | Sigma | Cat#: D5652-10X1L |
| 0.05% Trypsin + 0.53 mM EDTA | Corning | Cat#: 25-052-CI |
| **Deposited data** | | |
| NT₅₀ Values and De-identified patient data | SeroNet Coordinating Center, NCI, NIH | N/A |
| **Experimental models: Cell lines** | | |
| HEK293T | ATCC | Cat#: CRL-11268, RRID: CVCL_1926 |
| HEK293T-ACE2 | BEI Resources | Cat#: NR-52511, RRID: CVCL_A7UK |
| **Oligonucleotides** | | |
| CDC N1 F: 5’-GACCCCCAATCAGCGAAAT-3’ | Sigma-Aldrich | This paper |
| CDC N1 R: 5’-TCTGTTACTGCGAGTGAATCG-3’ | Sigma-Aldrich | This paper |
| CDC N2 F: 5’-TTACAAACATTGCCAGTTGAATCTG-3’ | Sigma-Aldrich | This paper |
| CDC N2 R: 5’-GCACACATCAGGGCGAAAG-3’ | Sigma-Aldrich | This paper |
| **Recombinant DNA** | | |
| pNL4-3-inGluc | David Derse, NCI, NIH Mazurov et al. (2010) | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_D614G | GenScript Biotech, Zeng et al. (2021a) | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_B.1.1.7 | GenScript Biotech, Zeng et al. (2021a) | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_B.1.351 | GenScript Biotech, Zeng et al. (2021a) | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_B.1.617.2 | GenScript Biotech, Evans et al. (2022) | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_BA.1.1 | GenScript Biotech, This paper | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_BA.1.1-ΔEPE | GenScript Biotech, This paper | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_BA.1 | GenScript Biotech, This paper | N/A |
| pcDNA3.1-SARS-CoV-2-Flag-S-Flag_BA.2 | GenScript Biotech, This paper | N/A |
| **Software and algorithms** | | |
| GraphPad Prism | Version 9.0.0 | GraphPad |

**RESOURCE AVAILABILITY**

**Lead contact**
Further information and requests for resources and reagents should be directed to the lead contact, Dr. Shan-Lu Liu (liu.6244@osu.edu).

**Materials availability**
Plasmids generated in this study are available upon request made to the lead contact.
Data and code availability

- NT_{50} values and de-identified patient information will be deposited to the National Cancer Institute SeroNet Coordinating Center. Additionally, NT_{50} values and de-identified patient information reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Vaccinated and patient cohorts

Summary data on HCW and COVID-19 patient cohorts is available in Table 1. Vaccinated HCW samples were collected under approved IRB protocols (2020H0228 and 2020H0527). Sera were collected 3–5 weeks post-second vaccine dose for 48 HCWs (24 female and 24 male) which included 20 Moderna mRNA-1273 and 28 Pfizer/BioNTech BNT162b2 vaccinated HCWs. In the study group, 19 HCWs received homologous vaccine booster doses 34–42 weeks post-second dose. Sera were then collected from these 19 HCWs (8 female, 11 male) 1–11 weeks post-vaccine booster dose. These samples included 6 Moderna mRNA-1273 and 13 Pfizer/BioNTech BNT162b2 boosted HCWs.

As previously described (Zeng et al., 2020), D614G wave ICU (n = 9) and hospitalized non-ICU (n = 9) patient samples were collected under an approved IRB protocol (OSU 2020H0228) between April and May of 2020. Patients did not provide consent for the collection of data on sex, gender, and age. Additionally, 18 Delta wave ICU patient samples (6 female and 12 male) were collected under an approved IRB protocol (2020H0175). Plasma samples were collected 3 days after ICU admission. Where detectable, the strain of SARS-CoV-2 infecting the ICU patients was determined by viral RNA extraction on nasal swabs with QIAamp MinElute Virus Spin kit followed by RT-PCR (CDC N1 F: 5′-TTACAAACATTGGCCGCAAA-3′; CDC N2 F: 5′-GCGCGACATTCCGAAGAA-3′; CDC N1 R: 5′-TCTGGTTACTGCCA GTTGAACTCTG-3′; CDC N2 R: 5′-TCTGGTTACTGCCA GTTGAACTCTG-3′; CDC N2 R: 5′-GCGCGACATTCCGAAGAA-3′) and Sanger sequencing to identify virus strain. Further, 31 Omicron wave hospitalized patient samples (11 female and 20 male) were collected under an approved IRB (2020H0527). Sera were collected 1–8 days after hospitalization for 31 COVID-19 patients admitted in late January and February of 2022. These included 15 unvaccinated patients. Additionally, 8 patients were vaccinated with two doses of the Pfizer/BioNTech BNT16b2 vaccine (n = 4) or Moderna mRNA-1273 vaccine (n = 4), and sample collection occurred 5–11 months (median 9 months) after 2nd vaccine dose. Finally, 8 patients were vaccinated with three doses of the Pfizer/BioNTech BNT16b2 vaccine and sample collection occurred 2–6 months (median 5 months) after booster vaccine administration.

Cell lines and maintenance

Female human embryonic kidney-derived HEK293T (ATCC CRL-11268, RRID: CVCL_1926) and HEK293T-ACE2 (BEI NR-52511, RRID: CVCL_A7UK) cells were maintained in DMEM (Gibco, 11965-092) supplemented with 10% FBS (Sigma, F1051) and 1% penicillin-streptomycin (HyClone, SV30010). Cells were maintained in 10 cm cell culture dishes (Greiner Bio-one, 664160) incubated at 37°C and 5.0% CO₂. Cells were passages by washing with Dulbecco’s phosphate buffer saline (Sigma, D5652-10X1L), followed by a 5 min incubation in 0.05% Trypsin + 0.53 mM EDTA (Corning, 25-052-CI) for splitting.

METHOD DETAILS

Plasmids

We utilized a previously reported pNL4-3-inGluc lentivirus vector which is based on ΔEnv HIV-1 and bears a Gaussia luciferase reporter gene that is expressed in virally infected target cells but not virus-producing cells (Goerke et al., 2008; Mazurov et al., 2010; Zeng et al., 2020). Additionally, SARS-CoV-2 variant spike constructs with N- and C-terminal flag tags were produced and cloned into a pcDNA3.1 vector by GenScript Biotech (Piscataway, NJ) using KpnI and BamHI restriction enzyme cloning. Specific mutations present in the pcDNA3.1-SARS-CoV-2-Flag-S-Flag constructs are presented in Figure 1A.

Pseudotyped lentivirus production

Lentiviral pseudotypes were produced as previously reported (Evans et al., 2022). Briefly, HEK293T cells were transfected with pNL4-3-inGluc and spike construct in a 2:1 ratio using polyethyleneimine transfection. Virus was harvested 24, 48, and 72 h after transfection. Relative virus titers were determined by infection of HEK293T-ACE2 cells, and Gaussia luciferase activity was assessed 48 h after infection by combining cell culture media with Gaussia luciferase substrate (0.1 M Tris pH 7.4, 0.3 M sodium ascorbate, 10 μM coelenterazine). Luminescence was immediately measured by a BioTek Cytation5 plate reader.

Virus neutralization assay

Pseudotyped lentivirus neutralization assays were performed as previously described (Evans et al., 2022; Zeng et al., 2020, 2021a, 2021b). HCW serum or ICU patient plasma samples were 4-fold serially diluted and equal amounts of infectious SARS-CoV-2 variant pseudotyped virus was added to the diluted serum. Final dilutions of 1:1280, 1:2560, 1:5120, 1:10240, and no serum control were used for Delta wave ICU patient plasma to avoid Triton X-100 toxicity, while final dilutions of 1:80, 1:320, 1:1280, 1:5120,
1:20480, and no serum control were used for the HCWs and all other patients. Virus and serum were incubated for 1 h at 37 °C and then transferred to HEK293T-ACE2 cells for infection. Gaussia luciferase activity was determined 48 and 72 h (technical duplicates) after infection by combining 20 μL or cell culture media with 20 μL of Gaussia luciferase substrate. Luminescence was immediately measured by a BioTek Cytation5 plate reader. NT_{50} values were determined by least-squares-fit, non-linear regression in GraphPad Prism 9 (San Diego, CA).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

All statistical analysis was performed using GraphPad Prism nine and are described in the figure legends. NT_{50} values were determined by least-squares fit non-linear regression in GraphPad Prism 9. Throughout, n refers to subject number and bars represent geometric means with 95% confidence intervals. Generally, comparisons between multiple groups were made using a one-way repeated measures ANOVA with Bonferroni post-test (Figures 1B, 1C, 2A, 2C, 2E, and 3A–3C) or one-way ANOVA with Bonferroni post-test (Figures 2F and 3H). Comparisons between two-groups were made using a paired two-tailed student’s t-test with Welch’s correction (Figures S1B–S1F). Comparisons between two “treatment” groups across multiple variants were made using a two-way repeated measures ANOVA with Bonferroni post-test (Figures 2D, S1A, and S1G). Due to small sample sizes, analysis of the influence of sex could not be performed without the influence of confounding variables including vaccination status, vaccine type, and time since vaccination skewing the analysis.